Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0052W HIGH $7.19
Volume
442.13 K
Value Traded
533.95 K
Short % Float
8.47%
-21.57%Week
-22.67%1 Month
-3.3%3 Month
+46.18%6 Month
-71.22%5 Year
-71.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
166.04 M
EPS (TTM)
-0.96
P/E Ratio
-
Ent. Value
86.18 M
Total Shares
37.74 M
Float Shares
28.30 M
Insiders
25.01%
Institutions
66.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ANTX Catalyst Timeline
Dated clinical, regulatory and corporate events for AN2 Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AN2 Therapeutics, Inc.
192Total events
15Upcoming
41Tier-1 (high impact)
2022 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingCorporate
Gates Foundation awards extension of funding for AN2/GSK TB research collaboration
tuberculosissource ↗
●Grant / FundingCorporate
Inducement equity awards granted to new CMO under NASDAQ Rule 5635(c)(4)
◆Oral PresentationEpetraborolePresentation
Four abstracts on epetraborole presented at SOHO 2026 Annual Meeting
polycythemia verasource ↗
◆Trial InitiationEpetraboroleTrial
Initiation of Phase 2 trial of epetraborole in polycythemia vera in India
polycythemia verasource ↗
◆Timing GuidanceEpetraborolePresentation
IND filing expected for Phase 2 EBO-PV-201 study of epetraborole in PV
polycythemia verasource ↗
▲Preclinical PoCAN2-502998Preclinical
Positive enabling data from 28-day NHP study showing parasite elimination in 100% of NHPs
chronic Chagas diseasesource ↗
▲First Patient DosedAN2-502998Trial
Phase 1 FIH study completed with favorable safety and tolerability
chronic Chagas diseasesource ↗
◆Oral PresentationPresentation
AN2 Therapeutics to present at 2026 Jefferies Global Healthcare Conference
▲Partnership / LicenseAN2-502998Corporate
Collaboration with DNDi for Phase 2 study
chronic Chagas diseasesource ↗
◆Trial InitiationTrial
Second oncology compound to enter development
Oncology (ENPP1 and PI3K targets)source ↗
▲Preclinical PoCAN2-502998Preclinical
Positive non-human primate efficacy data for AN2-502998 in chronic Chagas disease
chronic Chagas diseasesource ↗
▲PK PD DataAN2-502998Clinical Data
Favorable Phase 1 clinical pharmacokinetics and safety profile for AN2-502998
chronic Chagas diseasesource ↗
▲Trial InitiationEpetraboroleTrial
Phase 2 investigator-initiated trial commenced for M. abscessus lung disease
M. abscessus lung diseasesource ↗
▲Trial CompletionAN2-502998Trial
Phase 1 first-in-human clinical trial dosing completed
chronic Chagas diseasesource ↗
▲Development Candidate NominationPreclinical
ENPP1 candidate declared for solid tumors, advancing from early research into development
solid tumorssource ↗
◆Topline ReadoutAN2-502998Clinical Data
Data expected from non-human primate efficacy study
chronic Chagas diseasesource ↗
●Pre IND MeetingEpetraboroleFDA Meeting
AN2 held pre-IND meeting with FDA for epetraborole in polycythemia vera
polycythemia verasource ↗
●Enrollment UpdateEpetraboroleTrial
Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease
M. abscessus lung diseasesource ↗
▲Trial InitiationEpetraboroleTrial
Initiation of Phase 2 investigator-initiated clinical trial of epetraborole for M. abscessus lung disease
Mycobacterium abscessus complex lung diseasesource ↗
◆Oral PresentationPresentation
CEO to participate in fireside chat at Leerink Global Healthcare Conference
◆Topline ReadoutAN2-502998Clinical Data
Initial clinical data from Phase 1 trial of AN2-502998
Chagas diseasesource ↗
◆Trial InitiationEpetraboroleTrial
Initiation of enrollment for Phase 2 study of epetraborole in M. abscessus lung disease
M. abscessus complex lung diseasesource ↗
▲IND ClearanceEpetraboroleIND
FDA cleared IND for Phase 2 investigator-initiated study of epetraborole in M. abscessus lung disease
M. abscessus complex lung diseasesource ↗
▲First Patient DosedAN2-502998Trial
Phase 1 first-in-human clinical trial of oral AN2-502998 initiated
Chagas diseasesource ↗
▲Partnership / LicenseCorporate
Research collaboration with GSK to advance boron-based LeuRS-inhibitors targeting TB
Tuberculosissource ↗
▲Partnership / LicenseCorporate
Collaboration agreement with GSK to develop boron-based LeuRS-inhibitors for TB
tuberculosissource ↗
▲Trial InitiationAN2-502998Trial
Commenced Phase 1 first-in-human trial of AN2-502998 in healthy volunteers
Chagas diseasesource ↗
◆Trial InitiationEpetraboroleTrial
Phase 2 proof of concept study planned to initiate enrollment
acute melioidosissource ↗
◆Development Candidate NominationPreclinical
First oncology development candidate expected in 2H25
oncologysource ↗
●Trial InitiationAN2-502998Trial
Phase 1 start up activities for AN2-502998 in Chagas disease
Chagas diseasesource ↗
◆Trial InitiationAN2-502998Trial
Phase 1 first-in-human study of AN2-502998 to start mid-2025
Chagas diseasesource ↗
●Full ResultsEpetraboroleClinical Data
Key insights from observational trial announced
Melioidosissource ↗
●Additional DataEpetraboroleClinical Data
Key insights from observational trial announced
melioidosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ANTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | epetraborole | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$16M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 70%
Micro Cap(rank 462 of 660)
Percentile Rank
AN2 Therapeutics, Inc. faces pipeline headwinds (29/100), with $63M risk-adjusted pipeline value, led by AN2-502998 in Undisclosed (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AN2-502998 Small moleculeCompletedNCT07024589 | Undisclosed | Phase 1 | COMPLETED | 72 | Mar 14, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| epetraborole | polycythemia vera | 2026-08-31 | potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters; hematological and safety profile of epetraborole across healthy volunteers, non-PV patients, and nonhuman primate models; exposure-response relationships observed in nonhuman primates were predictive of effects subsequently observed in humansRead More | AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Readnour Robin ShaneDirector | Sell | -523 557,467 held | $6.02 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 1.4 % (55.6 %) | 15.26 M | 3.15 M |
ANTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ANTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANTX News
ANTXAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
AN2 Therapeutics has received an extension of funding from the Gates Foundation to continue its tuberculosis research collaboration with GSK. This partnership aims to develop boron-based therapeutics targeting leucyl-tRNA synthetase (LeuRS). The funding will support ongoing research activities, enhancing the potential for new treatments for TB.
Read more →ANTX▼ -8.2%on this news
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. has announced the granting of inducement equity awards to Dr. Cameron Trenor, its newly-appointed Chief Medical Officer. The awards include a non-qualified stock option for 233,333 shares and restricted stock units for 116,666 shares. This move is part of the company's strategy to attract and retain key talent.
Read more →ANTXAN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
AN2 Therapeutics has announced the presentation of four abstracts at the Society of Hematologic Oncology 2026 Annual Meeting. These abstracts will showcase clinical and nonclinical data supporting the development of epetraborole, an innovative oral treatment for polycythemia vera. This highlights the company's ongoing commitment to advancing novel therapeutics.
Read more →ANTXAN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
AN2 Therapeutics has appointed Dr. Cameron Trenor as Chief Medical Officer. With over 20 years of experience in clinical and translational development, Dr. Trenor is expected to enhance the company's leadership. His background in hematology and rare diseases will be valuable as AN2 continues to develop its novel therapeutics.
Read more →ANTX▲ +7%on this news
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported its financial results for Q2 2026, highlighting its progress in advancing three Phase 2 clinical programs by year-end. These programs are designed to tackle significant unmet medical needs, showcasing the company's commitment to innovation in small molecule therapeutics derived from its boron chemistry platform.
Read more →ANTXAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
AN2 Therapeutics announced positive results from studies on their oral therapeutic, AN2-502998, which targets chronic Chagas disease. The treatment achieved complete parasite elimination in 100% of nonhuman primates over a 28-day period, with a favorable safety profile demonstrated in Phase 1 human trials. The company is moving forward with plans to initiate a Phase 2 study, aiming to address the unmet medical need for an effective, well-tolerated treatment for this disease that affects millions globally. The promising data supports their goal of developing the first FDA-approved therapy for chronic Chagas disease in adults.
Read more →ANTX▲ +6.5%on this news
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
AN2 Therapeutics is scheduled to present at the 2026 Jefferies Global Healthcare Conference. Details regarding the presentation content or specific topics have not been disclosed. The event is expected to provide insights into the company's developments and future plans.
Read more →ANTX▲ +5.8%on this news
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics has released its financial results for the first quarter of 2026, along with updates on its business and scientific developments. The report highlights the company's ongoing efforts and strategies in the biopharmaceutical sector. Specific details regarding financial performance and scientific advancements were not disclosed in the provided text.
Read more →ANTXAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics is set to participate in the 2026 Stifel Virtual Targeted Oncology Forum. This event will provide a platform for the company to discuss its developments in oncology. Further details regarding the agenda or specific topics to be covered were not provided in the announcement.
Read more →ANTXAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
AN2 Therapeutics has announced the initiation of a Phase 2 investigator-initiated clinical trial for Epetraborole targeting Mycobacterium abscessus complex lung disease. This trial aims to evaluate the efficacy and safety of the treatment in affected patients. Further details regarding the trial design and expected outcomes were not disclosed.
Read more →ANTX▲ +6.6%on this news
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported its financial results for Q4 and full year 2025, highlighting the advancement of oral epetraborole into a Phase 2 study for polycythemia vera. The company is also preparing to initiate two additional Phase 2 studies in chronic Chagas disease and M. abscessus complex lung disease. Despite a reduced net loss compared to the previous year, the company continues to face financial challenges.
Read more →ANTX▲ +84.2%on this news
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics has announced a private placement financing expected to yield approximately $40 million. The deal involves selling over 8 million shares at $2.85 each, with participation from several institutional investors. The closing is anticipated on March 10, 2026, pending customary conditions. The company plans to register the shares for resale.
Read more →ANTX▲ +26.4%on this news· ran to +395% by day 3shared move
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics plans to advance oral epetraborole into a Phase 2 study for polycythemia vera (PV), a blood cancer. The study is expected to start in Q3 2026, with potential data readouts beginning in Q4 2026. Epetraborole has shown promising results in reducing hematocrit levels and is well tolerated in trials. The company aims to address the unmet needs in PV treatment.
Read more →ANTXAN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
AN2 Therapeutics, Inc. announced that its CEO, Eric Easom, will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026. The event will be accessible via webcast, with an archived replay available for 30 days. AN2 focuses on developing novel therapeutics from its boron chemistry platform for various diseases.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported its Q3 2025 financial results, highlighting advancements in its clinical programs. The company is progressing with its Phase 1 trial for AN2-502998 aimed at treating Chagas disease and plans to initiate a Phase 2 study. Additionally, a collaboration with GSK to target tuberculosis has been established, backed by renewed funding from the Gates Foundation. Financially, the company reported a net loss of $9 million for the quarter, reflecting reduced R&D costs due to decreased clinical trial expenses.
Read more →ANTXInvestor Overview June 2025 A N 2 T H E R A P E U T I C S . C O M Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
AN2 Therapeutics outlined its forward-looking strategy focusing on its boron chemistry platform at a recent investor overview. The presentation highlighted anticipated milestones in developing various therapies, including for Chagas disease and melioidosis. The company holds a strong financial position, with sufficient cash runway to support its programs into 2028. However, significant risks remain, including the uncertainty of regulatory approvals and timely patient enrollment in clinical trials.
Read more →ANTXAN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
AN2 Therapeutics reported the results from the Phase 3 EBO-301 study, which failed to meet its primary endpoint related to Quality of Life in patients with advanced MAC lung disease. Despite these disappointing outcomes, the company sees potential for its lead candidate, epetraborole, in other non-tuberculous mycobacterial diseases. AN2 is focusing on its boron chemistry pipeline, with plans for new clinical trials in Chagas disease and melioidosis. The company has extended its financial runway into 2028 and aims to optimize operational efficiency while pursuing new drug developments.
Read more →ANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting significant milestones in its drug development pipeline. The company anticipates topline data for its Phase 3 trial of epetraborole in patients with treatment-refractory MAC lung disease in Q2 2025, building on positive Phase 2 findings. A Phase 1 study for AN2-502998 targeting Chagas disease is expected to begin in mid-2025, along with a Phase 2 proof of concept trial for melioidosis planned for later in the year. The financial outlook remains stable, with expected cash reserves funding operations into 2027 despite a recorded net loss for the year.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline Epetraborole-treated patients demonstrated clinical improvements in
AN2 Therapeutics reported its financial results for the third quarter of 2024, highlighting significant clinical improvements in patients treated with its drug candidate epetraborole for treatment-refractory Mycobacterium avium Complex. The company plans to engage with the FDA to discuss the potential reinitiation of a pivotal Phase 3 clinical study. Additionally, AN2 has achieved a 50% reduction in expenditures and has sufficient cash resources to fund operations through 2027. The ongoing development of its boron chemistry pipeline was also emphasized, with plans for preclinical studies targeting chronic Chagas disease and melioidosis.
Read more →ANTXAN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
AN2 Therapeutics has implemented a limited duration stockholder rights plan set to expire on August 15, 2025, due to a significant accumulation of stock by BML Investment Partners, who hold 19.3% of the company's shares. This plan aims to ensure fair treatment of all stockholders and protect against any coercive control tactics. Under the plan, shareholders will receive rights enabling them to purchase preferred stock at a specific price, which can be triggered under certain acquisition scenarios. The announcement highlights the company’s focus on maintaining its governance and protecting its stockholder base amidst potential takeover threats.
Read more →About AN2 Therapeutics, Inc.
Headquarters1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next ANTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime